Xvivo Perfusion AB (publ) (XVIVO) Earnings Call Transcripts

Xvivo Perfusion AB (publ)'s Latest Earnings Call - Q1 FY2026

Xvivo Perfusion AB reported a strong Q1 2026 with a 23% organic revenue growth, translating to SEK 241 million in net sales. The company achieved a positive net cash flow for the second consecutive quarter. EBITDA margin was 21%, or 24% excluding nonrecurring costs related to heart launch preparations. Management highlighted significant progress in the thoracic and abdominal segments, with particular strength in lung and kidney sales. Guidance remains optimistic with continued investments in sales and clinical field force, aiming to expand market presence and regulatory approvals.

Reported metrics

Guidance from management

Management plans to continue building salesforce and partnerships, particularly in the U.S. They aim to submit the regulatory file for the heart assist to the FDA by summer and are optimistic about achieving CE-marking in Europe by early summer.

What management said

Thank you. Good question. We are sitting with the file right now. We don't -- I don't have an exact time line, but it will be somewhere during the summer. So I will come back when I have a better time line, but it's somewhere during the summer. So it's not the end of the year, it's earlier than that.

I can't speculate on what the FDA wants. We have to hand in the file and see what the feedback is and follow their process. It will be more or less impossible to speculate on what will happen or not. But I know last time we had an expert panel meeting, we fared very well on the lung side with [ 10-0, 10-0, 10-0 ]. So we know how to do this, and we are confident that we can answer any questions the FDA might pose to u...

What analysts pressed on

Analysts expressed concerns about the potential for destocking in EVLP sales and the impact of regional sales mix on abdominal gross margins. Questions were also raised about the timeline for FDA approval and potential market penetration for the heart assist device.

Main topics on the call

• Revenue Growth — Xvivo reported a 23% organic revenue growth, with SEK 241 million in net sales. Excluding the U.S. CAP trial, growth was 18%.
• Thoracic Segment Performance — Thoracic segment delivered record sales of SEK 160 million, with 27% organic growth. EVLP disposables grew 56%, driven by centralized perfusion hubs and key accounts.
• Abdominal Segment Growth — Abdominal segment saw 24% organic growth, with kidney sales up 63% in local currencies. However, gross margins were impacted by regional sales mix.
• Heart Assist Progress — The U.S. PRESERVE Trial met efficacy and safety endpoints, with severe PGD at 7.9%. European DCD trial showed 98% survival at 30 days.

Read the full Xvivo Perfusion AB (publ) transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 25 Xvivo Perfusion AB (publ) earnings call transcripts on record, spanning January 30, 2020 to July 14, 2026. Based on this history, Xvivo Perfusion AB (publ) reports quarterly. The most recent call on file is dated July 14, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

XVIVO

Exchange

OM

Country

SE

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

25

First call

January 30, 2020

Most recent

July 14, 2026

Reporting cadence

quarterly